Adhd

Florida

50 Adhd Trials near Florida

Power is an online platform that helps thousands of Adhd patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

NRCT-101SR for ADHD

Miami, Florida
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:13 - 17

160 Participants Needed

This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:4 - 5

168 Participants Needed

Centanafadine for ADHD

West Palm Beach, Florida
This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 18

680 Participants Needed

SPN-812 ER for ADHD

Maitland, Florida
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 18

1400 Participants Needed

This trial tests different ways to help children with ADHD behave better in school. It starts with general classroom techniques, adds more focused help if needed, and uses advanced methods or medication if necessary. The study targets young children with ADHD who are not in special education or on medication. Medication has been extensively studied and shown to improve ADHD symptoms in children.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

300 Participants Needed

Azstarys® for ADHD

Orlando, Florida
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:4 - 5

123 Participants Needed

This trial looks at how school adjustments, behavior techniques, and medicine help kids with ADHD do better in school. It focuses on children who have trouble paying attention and performing well academically. The treatments work by making school easier, encouraging good behavior, and helping kids focus better.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:5 - 12

288 Participants Needed

SPN-812 for ADHD

Tamarac, Florida
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:48 - 69

286 Participants Needed

TAK-503 for ADHD

Orlando, Florida
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:6 - 17

396 Participants Needed

Methylphenidate for ADHD

Gainesville, Florida
This trial is investigating how genetic differences in an enzyme called CES1 affect the way ADHD patients respond to the medication methylphenidate. The goal is to understand why some patients do not respond well or experience severe side effects. Methylphenidate (MPH) is a well-established treatment for ADHD, but not all patients respond to it, and some experience adverse reactions.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:6 - 17

500 Participants Needed

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:13 - 17

60 Participants Needed

The goal of this clinical trial is to compare the effect of language and behavioral interventions for students who are English language learners and who have symptoms of attention-deficit/hyperactivity disorder (ADHD). The main question it aims to answer is: - Which intervention is better for the students: the behavioral intervention, the language intervention, or a combination of the behavioral and language interventions? Participants will be asked to do the following: * Participants' parents and teachers will be asked to complete questionnaires about their behavior. * Participants will be asked to complete tests assessing language, cognitive, and academic abilities. * Members of the research team will complete classroom observations for the participating students. * Participants will be randomly assigned to one of four groups: a school as usual group, a language group, a daily report card group, and a combined daily report card and language group. * If assigned to the language group, participants will receive an 18-week language intervention. * If assigned to the daily report card group, a behavioral consultant will work with participants' parents and teachers to set up a home-school behavior plan called a daily report card. * If assigned to the combined daily report card and language group, participants will receive both the language intervention and the daily report card. * If assigned to the school as usual group, participants will no study interventions. Researchers will compare the language group, the daily report card group, the combined language and daily report card group, and the school as usual group to see which group has the best language learning and classroom behavior at the end of the program.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

CET + BPT for ADHD

Tallahassee, Florida
This trial combines a computer program to help kids with ADHD improve their memory and focus with a training program for parents to better manage their child's behavior. The goal is to see if using both treatments together can provide greater benefits for children with ADHD and their families.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 12

200 Participants Needed

This trial is testing a video game that adults with ADHD can play at home to help manage their symptoms. The game aims to improve attention and reduce hyperactivity by training the brain. Researchers are studying if this new approach is safe and effective. The Secret Trail of Moon (TSTM) is a virtual reality game designed for cognitive training related to core ADHD symptoms and executive dysfunction.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22 - 55

194 Participants Needed

The goal of this project is to assess impact of an 8 week course of Preksha Meditation (combination of Green color and buzzing sound meditation), in a group of college students to assess potential benefits to their pulmonary function, cognitive ability (immediate recall, attention), and happiness.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 24

142 Participants Needed

Methylphenidate for Alcoholism

Gainesville, Florida
The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcohol cues. The study will observe the effects of methylphenidate or a placebo on attentional bias and craving responses to alcohol cues through fMRI, EEG, and behavioral testing. Participants will be involved in one remote and two in-person sessions.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 25

30 Participants Needed

The goal of this randomized study is to learn if adding three additional parent training sessions (focused on alleviating parental stress) to an already well-established treatment (School Readiness Parenting Program \[SRPP\]) in improving outcomes up to 6- and 12-months later for families of children with disruptive behavior disorders. The main questions it aims to answer are: The primary objective of this protocol is to evaluate the effects of three additional cognitive behavioral therapy (CBT) based parent training sessions to the SRPP to reduce parent stress and improve parent-child interactions. The secondary objective of this protocol is to evaluate the behavioral, emotional, and physical health-based functioning among young children with ADHD. Researchers will compare families who receive the SRPP alone to families who receive the SRPP + the three additional CBT focused sessions. Parents will be sent surveys to complete prior to the baseline assessment via REDCap (online). Parent and child participants will undergo 2 hours of baseline assessments evaluating behavioral, cognitive, and academic functioning as well as parent-child interactions. Parents will provide contact information for their child's teacher and the teacher will sent three surveys to complete online via REDCap.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:4 - 6

120 Participants Needed

80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of alcohol-related problems, HIV and other sexually transmitted infections (STIs). Participants will then take pre-exposure prophylaxis (PrEP) for HIV prevention and complete a daily 5-minute, telephone-based interactive voice response (IVR) assessment of alcohol/substance use, sexual behavior and PrEP taking for 30 days. Medication will all be active PrEP. There is no placebo control in this study. Follow-up will occur after 30-days and 6-months later.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 30
Sex:Male

88 Participants Needed

Entertainment media commonly depict SU, and youth exposure to media SU is linked to youth initiation and progression of SU behavior. Parenting practices reduce exposure to and may mitigate risk associated with media depictions of SU, thus this research proposal will build upon current understanding of effective media parenting with the end goal of developing and testing a media parenting intervention designed to reduce youth risk for SU.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 14

120 Participants Needed

This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE®) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE®). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

122 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50
The goal of this study is to evaluate the efficacy of stepped care strategies to improve ART adherence among adult Latino MSM with HIV using a sequential, multiple assignment, randomized trial (SMART). The trial will compare a stepped care strategy of delivering TXTXT ("Treatment Text") first and stepping up to remote patient navigation for non-responders vs. a stepped care strategy of delivering TXTXT + e-Navigation first and stepping up to EMA-supported e-Navigation for non-responders. Both TXTXT and the foundations of the e-Navigation interventions are CDC evidence-based interventions (EBI). We propose to use a SMART design which explicitly allows building, testing, and optimizing stepped care strategies without compromising rigor or randomization. We propose three specific aims: Aim 1. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two static (non-stepped) treatment regimens (TXTXT alone vs. TXTXT + e-Navigation) on ART adherence and viral suppression among Latino MSM with HIV. Hypothesis 1a. TXTXT + e-Navigation will be more efficacious than TXTXT alone. Aim 2. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two stepped care strategies (TXTXT with added e-Navigation for non-responders vs. TXTXT + e-Navigation with added EMA support for non-responders) on ART adherence and viral suppression among Latino MSM with HIV. Hypothesis 2a: TXTXT + e-Navigation with added EMA support for non-responders at the 3-month follow-up will be more efficacious than TXTXT with added e-Navigation for non-responders at the 3-month follow-up. Aim 3. Identify baseline and time-varying moderators on the association between stepped care strategy and ART adherence and viral suppression among Latino MSM with HIV. Hypotheses 3a-c: TXTXT with added e-Navigation for non-responders will be less efficacious than TXTXT + e-Navigation with added EMA support for non-responders for individuals who are: (a) older at baseline, or report (b) substance use, or (c) symptoms of depression between baseline and the 3-month follow-up.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Sex:Male

250 Participants Needed

The purpose of this study is to learn about ways to better support people living with HIV with their HIV treatment and cope with mental health challenges and/or substance use concerns.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

75 Participants Needed

This trial tests a new program called PARTI, which combines mood-boosting sessions with a smartphone app that helps men who use stimulants take their HIV prevention medication regularly. The goal is to see if this approach can lower their risk of getting HIV.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Sex:Male

239 Participants Needed

The purpose of this study is to test how different types of interventions may affect how someone takes their pre-exposure prophylaxis (PrEP) medication.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Sex:Male

250 Participants Needed

During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

80 Participants Needed

The primary objective of this study is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and infant outcomes. The primary hypothesis is that the BUP-XR group will not have greater illicit opioid use than the BUP-SL group during pregnancy (non-inferiority).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 41
Sex:Female

140 Participants Needed

Negative pressure wound therapy (NPWT) is widely used for chronic and acute wounds, severe burns, and post-operative care. Despite its benefits, the strong adhesive required to maintain an airtight seal increases the risk of medical adhesive-related skin injuries (MARSI), pain, and discomfort during removal. Global Biomedical Technologies (GBT) aims to develop an NPWT drape with "switchable adhesive" technology to enhance removal while maintaining an effective seal. This innovation is expected to benefit both single-use and serial-use NPWT applications by reducing MARSI and improving patient comfort. This project will compare the functionality and acceptability of Comfort Release® NPWT drapes with the industry-standard V.A.C. drape (KCI Technologies, Inc.) in a non-blinded randomized controlled trial. Specific Aims Aim 1: Compare Comfort Release® drapes with V.A.C. drapes in single-use NPWT applications in post-surgical patients (n=200) at Columbia University Medical Center and Weill Cornell Medical Center. Milestones: Demonstrate statistically significant (α=0.05) improvement over V.A.C. drapes in: Reduction of MARSI (Medical Adhesive-Related Skin Injury scoring system) Decreased pain (Indiana Polyclinic Combined Pain Scale) Reduced need for pain/anxiety medication Equivalent or improved seal effectiveness (leak incidence rate) Clinician acceptability Aim 2: Compare Comfort Release® drapes with V.A.C. drapes in serial-use NPWT applications in chronic wound patients (n=100) at Weill Cornell Medical Center. Patients will undergo three NPWT drape changes per week. Milestones: Demonstrate statistically significant (α=0.05) improvement over V.A.C. drapes in: Reduction of MARSI Decreased pain (Indiana Polyclinic Combined Pain Scale) Improved compliance with treatment duration Reduced need for pain/anxiety medication Equivalent or better seal effectiveness Clinician acceptability (questionnaire score \>4) Reduced nursing time by ≥20% Economic value through time and cost savings At each dressing change and final removal, qualitative data from clinicians will assess the acceptability and usability of Comfort Release® NPWT drapes.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

The goal of this clinical trial is to learn if two interventions-C4 and C4+3MV-can improve PrEP adherence (taking medication to prevent HIV) among Black men who have sex with men (MSM). The study will also explore the most effective ways to support participants in continuing their PrEP use over time. The main questions it aims to answer are: * Does the C4 program help participants take PrEP more regularly? * Does adding the 3MV intervention to C4 provide additional support for adherence? Researchers will compare two intervention strategies to see if they result in better PrEP adherence: * C4 Intervention: A program focused on individualized care coordination and addressing structural needs. * C4 + 3MV Intervention: A combination of care coordination with additional behavioral change sessions. Participants will: * Participate in PrEP education and counseling sessions. * Have their PrEP use monitored through dried blood spot (DBS) tests. * Complete questionnaires about their experiences and challenges with PrEP. Receive support sessions tailored to address individual barriers to PrEP adherence.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Sex:Male

500 Participants Needed

This Phase II randomized controlled trial is testing the efficacy of a cell phone application called START for helping men who use stimulants like methamphetamine to get the most out of their HIV treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Sex:Male

286 Participants Needed

The overall goal of this study is to evaluate the effectiveness of a previously developed storytelling intervention on anticoagulation (AC) initiation/persistence in African American and Black patients with atrial fibrillation/flutter. The investigators hope to gain knowledge that may help treat atrial fibrillation or flutter and lower stroke and adverse cardiovascular event risks for African American and Black patients by increasing the use of blood thinning medications known as anticoagulants.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

80 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Adhd clinical trials in Florida pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Adhd clinical trials in Florida work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Adhd trials in Florida 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Florida for Adhd is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Florida several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Adhd medical study in Florida?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Adhd clinical trials in Florida?

Most recently, we added PrEP Adherence Programs for HIV Prevention, Massed Prolonged Exposure Therapy for PTSD and Substance Addiction and T.E.C.H. Parenting for Substance Abuse to the Power online platform.

How to manage ADHD without Adderall?

Think of ADHD care without Adderall as three pillars: 1) proven skills training such as cognitive-behavioral therapy or parent/teacher coaching, which meta-analyses show can meaningfully cut inattentive and impulsive symptoms; 2) daily habits that boost brain chemicals—consistent aerobic exercise, 7-9 hours of sleep, and a balanced, low-sugar diet—each backed by research to modestly improve focus; 3) targeted add-ons (omega-3 fish-oil supplements, mindfulness practice, or professionally guided neurofeedback) that have small but credible benefits for some people. Work with a clinician to combine, test, and adjust these pieces every few months so you know what is actually helping and can add non-stimulant medicines later if needed.

Are we over diagnosing ADHD?

Rates of ADHD diagnosis have climbed, and studies confirm that some children—especially the youngest in a class or from more advantaged families—get the label and medication they may not truly need. At the same time, girls, adults, and many minorities with real symptoms are often missed, so the issue is less “too much” diagnosis overall and more “diagnosis in the wrong people.” Asking for a full evaluation that checks symptoms in several settings and rules out sleep, mood, or learning problems is the best safeguard against both mistakes.

What is the latest research on ADHD?

Recent work is mapping ADHD on two fronts: cause and treatment. On the biology side, a 2023 genome-wide study involving >40 000 people pinpointed 30+ gene regions, MRI scans show disrupted communication between attention- and reward-circuits, and several studies find distinct gut-bacteria patterns in both kids and adults—together suggesting ADHD arises from a mix of genes, brain-network wiring and (still-early) gut influences. Translating this, clinicians now have newer options beyond classic stimulants—FDA-approved viloxazine XR, long-acting patches, the prescription video-game EndeavorRx, and small but promising trials of neurofeedback and cognitive training—so ask your doctor about standard medications plus these emerging tools that may soon allow more personalized care.

Does Johnny Depp have ADHD?

There is no credible public record—interview, court document, or medical statement—showing that Johnny Depp has been formally diagnosed with ADHD; the claim stems from unsourced online lists that repeat each other. Until Depp or a qualified clinician confirms otherwise, any statement that he “has ADHD” should be treated as unverified speculation; if you need information about ADHD, rely on a licensed health professional, not celebrity rumors.

What is the 80 20 rule ADHD?

For someone with ADHD, the 80/20 rule means spotting the 20 % of tasks or habits that create about 80 % of your desired results—then protecting time and attention to do those first, ideally when your medication or energy is at its peak. This cuts overwhelm because you give yourself permission to ignore low-impact busywork and instead break the high-impact tasks into small, doable steps (using timers, alerts, or an accountability partner). Think of it as a focusing lens, not a cure; pair it with your regular ADHD treatments and adjust the “vital 20 %” as your goals change.

Is ADHD a disability?

Yes—ADHD is treated as a disability when the symptoms are strong enough to “substantially limit” everyday activities like focusing, learning, or working, which is exactly how U.S. laws such as the ADA, Section 504, and Social Security define disability. A diagnosis alone isn’t enough; you need documentation that the condition is causing real-world problems, after which schools, employers, or benefit programs must consider reasonable supports (extra time, quiet workspace, flexible scheduling, etc.). If you think ADHD is holding you back, gather medical records and examples of how it affects your tasks and formally ask for accommodations or benefits under the relevant program.

What makes ADHD people happy?

Studies show that people with ADHD feel happiest when four things line up: (1) their core symptoms are tamed with medication and/or ADHD-specific therapy, (2) predictable routines, reminders, exercise, and good sleep cut daily chaos, (3) they spend real time in activities that match their high interests and creativity, and (4) they’re surrounded by family, friends, or support groups that understand ADHD rather than shame it. Put simply: treat the symptoms, externalize organization, lean into your passions, and stay connected to people who “get” you—those combined levers consistently raise quality-of-life scores for both kids and adults with ADHD.

How much weight did you lose on ADHD medication?

Weight loss on stimulant ADHD medicines is usually modest and highly individual—clinical trials show average drops of about 3–5 lb (1–2 kg) in the first month and roughly 6–10 lb (3–4 kg) over the first 3–6 months, with only one-third of people losing more than 5 % of their starting weight before the effect levels off. Weigh yourself (or your child) weekly; if you see more than a 10 % fall from baseline or a slowdown in growth, talk with the prescriber about dose timing, nutrition strategies, or switching to a non-stimulant option.

What makes ADHD worse in adults?

Anything that further strains the brain’s self-regulation system can flare adult ADHD: lack of sleep or exercise, chronic stress, unmanaged anxiety/depression, inconsistent medication or substance use, hormonal shifts, and chaotic, screen-heavy environments. Focus on the controllables—protect 7-9 h of sleep, move daily, eat regular balanced meals, keep spaces and schedules simple, treat co-existing mood issues, and take medication exactly as prescribed—then review persisting problems with your clinician.

Is there still ADHD med shortage?

Yes—into 2024 many pharmacies still report spot shortages of popular stimulant ADHD medicines, especially immediate-release Adderall, several methylphenidate/Concerta generics, and some Vyvanse doses, because factory slow-downs and federally capped production haven’t kept up with rising prescriptions. Availability varies week-to-week and by location, so call a few pharmacies early, ask if a different strength or brand is in stock, and have your prescriber ready to adjust the prescription or discuss a short-term non-stimulant alternative if needed.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security